Mono Pharmacare (NSE:MONOPHARMA) Long-Term Debt: ₹264 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
9 GF Score
Price ₹7.85
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Long-Term Debt?

Mono Pharmacare NSE:MONOPHARMA 9 Long-Term Debt is ₹264 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Mono Pharmacare's Long-Term Debt for the quarter that ended in Sep. 2025 was ₹264 Mil.

Mono Pharmacare's quarterly Long-Term Debt increased from Sep. 2024 (₹219 Mil) to Mar. 2025 (₹260 Mil) and increased from Mar. 2025 (₹260 Mil) to Sep. 2025 (₹264 Mil).

Mono Pharmacare's annual Long-Term Debt declined from Mar. 2023 (₹180 Mil) to Mar. 2024 (₹171 Mil) but then increased from Mar. 2024 (₹171 Mil) to Mar. 2025 (₹260 Mil).

Mono Pharmacare  (NSE:MONOPHARMA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Mono Pharmacare Long-Term Debt Related Terms

Mono Pharmacare Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Long-Term Debt Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Long-Term Debt
9.86 15.14 180.10 171.25 259.61

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only 178.04 171.25 219.16 259.61 264.39
NSE:MONOPHARMA
9GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹264 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Long-Term Debt of ₹264 Mil as of Sep. 2025.
Is Mono Pharmacare's Long-Term Debt too high?
Mono Pharmacare's current Long-Term Debt is ₹264 Mil. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Long-Term Debt compare to competitors?
Mono Pharmacare's Long-Term Debt of ₹264 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Mono Pharmacare's current Long-Term Debt is ₹264 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Long-Term Debt of ₹264 Mil. The current Long-Term Debt is ₹264 Mil. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Long-Term Debt is ₹264 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score

Get the complete analysis for NSE:MONOPHARMA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7.85
Price